Article type:
Home Page URL: https://www.alliedacademies.org/journal-clinical-oncology-cancer-research/

Personalized Cancer Vaccines: Emerging Trends and Clinical Trial Outcomes.

Reynolds Michael A*

Department of Oncology, School of Medicine, Westbridge University, United States

***Correspondence to:** Reynolds Michael A. Reynolds. Department of Oncology, School of Medicine, Westbridge University, United States. Email: michael.reynolds@med.univ.edu`

Received: *27-May-2025, Manuscript No. AACOCR-25-169763;* ***Editor assigned:*** *01-Jun-2025, PreQC No. AACOCR-25-169763 (PQ);* ***Reviewed:*** *15- Jun-2025, QC No. AACOCR-25-169763;* ***Revised:*** *22- Jun-2025, Manuscript No. AACOCR-25-169763 (R);* ***Published:*** *29- Jun-2025, DOI:10.35841/AACOCR-8.1.185*

Introduction

Cancer immunotherapy has evolved rapidly over the past decade, with personalized cancer vaccines emerging as one of the most promising innovations. Unlike conventional therapeutic approaches, personalized cancer vaccines are designed to target tumor-specific neoantigens identified from an individual's tumor genome. This precision strategy aims to stimulate a patient's immune system to recognize and eliminate malignant cells with minimal impact on healthy tissue. Advances in genomic sequencing, bioinformatics, and artificial intelligence have made it feasible to identify and prioritize immunogenic epitopes within weeks, enabling timely vaccine production. Early-phase clinical trials in melanoma, non-small cell lung cancer, and glioblastoma have shown encouraging results, with several candidates demonstrating improved immune responses, reduced tumor recurrence rates, and favorable safety profiles. The integration of mRNA vaccine technology, previously accelerated by the COVID-19 pandemic, has further streamlined the manufacturing process, paving the way for broader clinical applications [1, 2, 3, 4, 5].

Conclusion

Personalized cancer vaccines represent a paradigm shift in oncology, moving toward highly targeted, patient-specific treatments that leverage the body's natural immune defense. While initial clinical trial outcomes are promising, large-scale randomized studies are essential to validate efficacy, optimize dosing regimens, and identify patient populations that will benefit most. Continued advancements in biomarker discovery, AI-driven epitope prediction, and combination therapies with immune checkpoint inhibitors are expected to enhance clinical outcomes. As research progresses, personalized cancer vaccines hold the potential to transform cancer care from a generalized approach to one of precise, durable, and individualized disease control.

References

1. Becker, D. E., & Reed, K. L. (2012). Local anesthetics: Review of pharmacological considerations. *Anesthesia Progress*, 59(2), 90–101.
2. Moore, P. A., & Hersh, E. V. (2010). Local anesthetics: Pharmacology and toxicity. *Dental Clinics of North America*, 54(4), 587–599.
3. Joshi, A., & Eipe, N. (2020). Efficacy of long-acting local anesthetics in postoperative pain management: A review. *Journal of Oral and Maxillofacial Surgery*, 78(9), 1584–1591.
4. Malamed, S. F. (2013). Handbook of local anesthesia (6th ed.). Elsevier Health Sciences.
5. Tong, D. C., & Alzahrani, F. S. (2017). The effect of bupivacaine on postoperative pain following third molar surgery: A systematic review and meta-analysis. *Journal of Oral and Maxillofacial Surgery*, 75(5), 915–924.

Citation: Michael A R. Personalized Cancer Vaccines: Emerging Trends and Clinical Trial Outcomes. *J Oral Med Surg*. 2025; 8(1):185